Acumen Pharmaceuticals (ABOS) Profit After Tax (2020 - 2026)

Acumen Pharmaceuticals has reported Profit After Tax for 7 years, with the latest figure at -$20.8 million in Q1 2026.

• Quarterly Profit After Tax rose 27.61% year-over-year to -$20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$113.3 million (up 2.99% YoY) and the FY2025 annual result came in at -$121.2 million, down 18.03% from the prior year.
• Profit After Tax climbed to -$20.8 million in Q1 2026 per ABOS's latest filing, from -$25.2 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$9.7 million in Q1 2022 and troughed at -$40.9 million in Q2 2025.
• A 5-year average of -$20.1 million and a median of -$16.5 million in 2023 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 83.46% in 2022, down 174.47% in 2022.
• Over 5 years, Profit After Tax stood at -$12.9 million in 2022, then fell by 28.22% to -$16.5 million in 2023, then slumped by 128.65% to -$37.7 million in 2024, then surged by 33.29% to -$25.2 million in 2025, then gained by 17.35% to -$20.8 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$20.8 million, -$25.2 million, and -$26.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.